Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 2Phase 3 1

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2NIH 2INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Papillomavirus Infections 2Leukemia, Lymphocytic, Chronic, B-Cell 1Human Papillomavirus-Related Cervical Carcinoma 1Advanced Fallopian Tube Carcinoma 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Diphtheria-Tetanus-acellular Pertussis Vaccines × Clear all
NCT05237947 2026-05-22

PRISMA

National Cancer Institute (NCI)

Phase 4 Active not recruiting
5,000 enrolled
Gynecologic

Human Papillomavirus-Related Cervical Carcinoma

NCT02518555 2026-04-06

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
42 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06639074 2025-10-02

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Mayo Clinic

Phase 2 Recruiting
78 enrolled
GynecologicSarcoma

Advanced Fallopian Tube Carcinoma

NCT03180034 2025-09-04

ESCUDDO

National Cancer Institute (NCI)

Phase 4 Active not recruiting
27,945 enrolled

Papillomavirus Infections

NCT01627561 2020-04-10

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

GlaxoSmithKline

Phase 3 Completed
148 enrolled 28 charts

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡